23:44 , Jun 22, 2018 |  BC Extra  |  Company News

Roche taps gRED’s Sabry as global head of partnering

A newly created global head of partnering role at Roche (SIX:ROG; OTCQX:RHHBY) is set to combine the pharma’s partnering functions for the first time since it completed its acquisition of Genentech Inc. James Sabry, head...
18:53 , Jun 8, 2018 |  BC Week In Review  |  Company News

Microbiotica, Genentech in microbiome deal

Genentech Inc. partnered with Microbiotica Ltd. (Cambridge, U.K.) to discover targets and therapeutics for inflammatory bowel disease (IBD) using Microbiotica’s precision metagenomics microbiome platform. Microbiotica will analyze patient samples from the Roche (SIX:ROG; OTCQX:RHHBY) unit’s...
19:51 , Jun 6, 2018 |  BC Extra  |  Company News

Microbiotica, Genentech in microbiome deal

Genentech Inc. partnered with Microbiotica Ltd. (Cambridge, U.K.) to discover targets and therapeutics for inflammatory bowel disease (IBD) using Microbiotica’s precision metagenomics microbiome platform. Microbiotica will analyze patient samples from the Roche (SIX:ROG; OTCQX:RHHBY) unit’s...
18:33 , May 11, 2018 |  BC Week In Review  |  Company News

Lodo, Genentech partner on R&D for microbial-derived therapies

Lodo Therapeutics Corp. (New York, N.Y.) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) partnered to discover compounds with Lodo's Metagenomics Technology Platform against multiple undisclosed targets chosen by Genentech. The collaboration could potentially...
12:02 , May 9, 2018 |  BC Extra  |  Company News

Lodo, Genentech partner on R&D for microbial-derived therapies

Lodo Therapeutics Corp. (New York, N.Y.) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) partnered to discover compounds with Lodo's Metagenomics Technology Platform against multiple undisclosed targets chosen by Genentech. The collaboration could potentially...
22:48 , Mar 9, 2017 |  BC Innovations  |  Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
07:00 , May 9, 2016 |  BioCentury  |  Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...
08:00 , Jan 25, 2016 |  BioCentury  |  Strategy

Formative years

VCs that spend a large chunk of their time and capital creating companies from scratch are planning to continue regardless of what happens with the financial markets. Although de novo company formation takes a lot...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Financial News

Lodo Therapeutics completes venture financing

Lodo Therapeutics Corp. , New York, N.Y.   Business: Infectious, Endocrine/Metabolic, Cancer   Date completed: 2016-01-11   Type: Venture financing   Raised: $17 million  ...
02:45 , Jan 12, 2016 |  BC Extra  |  Financial News

Accelerator debuts Lodo

Accelerator Corp. (Seattle, Wash.) formed its second New York City biotech with the launch of Lodo Therapeutics Corp. , which is developing small molecules from microbial sources such as soil bacteria and the human microbiome....